Start-Up Previews (4/03)
Executive SummaryA preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Orphan Drugs, features profiles of Amicus Therapeutics Inc., Myomatrix Therapeutics LLC and Vipogen LLC. Plus these Start-Ups across Health Care: Advagen Inc., Aviva Biosciences Corp., Gene Network Sciences Inc., Hypnion Inc. and Savacor Inc.
You may also be interested in...
House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.
The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.
The US Senate on a 72-18 vote approved radiation oncologist Stephen Hahn as Commissioner of the FDA on 12 December. Voting “no” were a block of liberal Democrats, including the ranking member of a key Senate health committee. Industry advocates and most senators said Hahn is an excellent choice to lead the FDA, but some fear he will not move quickly enough to ban candy flavors in vaping products favored by teens.